Dec. 1 at 6:00 PM
$VYNE As of late November 2025, VYNE Therapeutics' market capitalization is approximately
$12.83 million, while it has
$32.7 million in cash and cash equivalents and essentially no debt.
Here is a breakdown of the key financial figures:
Market Capitalization: Approximately
$12.83 million (as of December 1, 2025).
Cash on Hand:
$32.7 million in cash, cash equivalents, and marketable securities (as of the Q3 2025 report dated September 30, 2025).
Debt: The company has no significant debt ("n/a" in financial reports), placing it in a net cash position of
$32.7 million.
In summary, VYNE Therapeutics' cash on hand significantly exceeds its market capitalization, and the company carries virtually no debt.
